Special Reports in Personalized Cancer Care | Specialty

Dr. Salani on Opportunities for Precision Medicine in Cervical Cancer

June 11th 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

June 9th 2020

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Dr. Lopategui on the Evolution of Targeted Therapies in NSCLC

June 5th 2020

Jean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.

Analysis Highlights Acquired Resistance Mechanisms in METex14+ NSCLC

June 5th 2020

Mark M. Awad, MD, PhD, discusses the findings from the study, the importance of identifying patients with METex14 mutations, and the importance of understanding acquired resistance in NSCLC.

Dr. Stadler on the Utility of Germline Profiling for Targeted Interventions in Advanced Cancer

June 5th 2020

Zsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

Review Reveals Challenges of NGS Testing in Community Practices, Proactive Measures to Increase Utility

June 3rd 2020

Jennifer Marie Suga, MD, discusses the importance of understanding the current limitations to next-generation sequencing in oncology, the impact of the study findings, and remaining challenges regarding NGS testing in the community setting.

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

CD71-Directed Probody-Drug Conjugate Shows Safety, Signals of Activity in Advanced Solid Tumors

June 2nd 2020

The CD71-directed probody-drug conjugate of monomethyl auristatin E CX-2029 showed tolerability and antitumor activity in patients with advanced cancer.

Systematic Review Spotlights Potential Markers for ctDNA Use in CRC

June 2nd 2020

Sander Bach, discusses the rationale for conducting this systematic review in CRC, key inclusion/exclusion criteria, and the potential clinical implications of these findings.

EU Panel Backs Entrectinib for NTRK+ Tumors and ROS1+ NSCLC

June 1st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non–small cell lung cancer not previously treated with ROS1 inhibitors.